ECSP003373A - HIV THERAPY - Google Patents
HIV THERAPYInfo
- Publication number
- ECSP003373A ECSP003373A ECSP003373A ECSP003373A EC SP003373 A ECSP003373 A EC SP003373A EC SP003373 A ECSP003373 A EC SP003373A EC SP003373 A ECSP003373 A EC SP003373A
- Authority
- EC
- Ecuador
- Prior art keywords
- hiv
- effective amount
- combination
- therapeutically effective
- interferon alfa
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 3
- 108010047761 Interferon-alpha Proteins 0.000 abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 2
- 238000002651 drug therapy Methods 0.000 abstract 2
- 229950000038 interferon alfa Drugs 0.000 abstract 2
- 229960000329 ribavirin Drugs 0.000 abstract 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 2
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen los usos del interferón alfa, solo y en combinación con una farmacoterapia contra el HIV-1 y la ribavirina para la preparación de un medicamento para el tratamiento de pacientes que no han experimentado tratamientos y pacientes adultos y pediátricos infectados por el HIV-1que no han experimentado tratamientos así como pacientes coinfectados con HIV-1 y HCV, que comprende una cantidad terapéuticamente efectiva de interferón alfa pegilado, por ejemplo interferón alfa-2b pegilado, como monoterapia o, preferentemente, en combinación con una cantidad terapéuticamente efectiva de por lo menos una entre ribavirina, IL-2, IL-12 y pentafusida sola o en combinación con una cantidad terapéuticamente efectiva de una farmacoterapia contra el HIV-1, por ejemplo HAART.The uses of interferon alfa, alone and in combination with a drug therapy against HIV-1 and ribavirin for the preparation of a drug for the treatment of patients who have not undergone treatments and adult and pediatric patients infected with HIV-1, are described. they have not undergone treatments as well as patients co-infected with HIV-1 and HCV, which comprises a therapeutically effective amount of pegylated interferon alfa, for example pegylated interferon alfa-2b, as monotherapy or, preferably, in combination with a therapeutically effective amount of less one between ribavirin, IL-2, IL-12 and pentafuside alone or in combination with a therapeutically effective amount of a drug therapy against HIV-1, for example HAART.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003373 ECSP003373A (en) | 2000-03-01 | 2000-03-01 | HIV THERAPY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003373 ECSP003373A (en) | 2000-03-01 | 2000-03-01 | HIV THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003373A true ECSP003373A (en) | 2001-05-23 |
Family
ID=42041004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003373 ECSP003373A (en) | 2000-03-01 | 2000-03-01 | HIV THERAPY |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003373A (en) |
-
2000
- 2000-03-01 EC ECSP003373 patent/ECSP003373A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023824A1 (en) | HIV THERAPY COMBINATION OF ANTAGONIST CCR5-INTERFERON ALFA PEGILADO. | |
| AR023541A1 (en) | HCV COMBINATION THERAPY | |
| PE119199A1 (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| UA29429C2 (en) | Pharmaceutical composition for treatment of viral infections, method for preparation of composition, method for treatment or prophylaxis of aids in human | |
| CO4940414A1 (en) | THERAPY OF MODIFIED POLYETHYLENE GLYCOL INTERFERONS | |
| DE69632256D1 (en) | ANTIVIRAL PROTEINS, CODING DNA, AND THEIR USE | |
| BR9913932A (en) | Use of glp-1 analogs in the treatment of stroke | |
| BRPI0418157A (en) | allogeneic tumor therapy | |
| WO2002034284A3 (en) | Methods of therapy for hiv infection | |
| BR0108499A (en) | Hepatitis c therapeutic agent | |
| CO5160259A1 (en) | INTERFERON ALFA PEGILADO IN THE THERAPY AGAINST HIV | |
| AR022250A1 (en) | PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B. | |
| BR0108997A (en) | Adjuvant Immune Therapy for HIV | |
| ECSP003373A (en) | HIV THERAPY | |
| ES2185310T3 (en) | HERBAL ANTIVIRICAL AGENT. | |
| AR029160A1 (en) | THE USE OF PEGILATED INTERFERON-ALFA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RENAL CELL CARCINOMA, A KIT AND THE USE OF IT | |
| ZA200708539B (en) | Methods of applying ionization radiation for therapy of HIV infection | |
| AR013498A1 (en) | USE OF IFN-ALPHA AND AMANTADINE FOR THE TREATMENT OF CHRONIC HEPATITIS C USE OF IFN-ALPHA | |
| ECSP003462A (en) | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) | |
| PT1150981E (en) | THERAPEUTIC NUCLEOSIDAL COMPOSITION | |
| AR023398A1 (en) | MELANOMAS THERAPY | |
| DE69130571D1 (en) | Peptides that inhibit human immunodeficiency virus and how to use it | |
| IL154299A0 (en) | Treatment of hepatitis c with thymosin, interferon and ribavirin | |
| AR023390A1 (en) | THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA | |
| ECSP003446A (en) | COMBINATION THERAPY FOR HCV |